Under the agreement, Lupin would exclusively market Enoxaparin Sodium Injection in pre-filled syringes under the brand name 'Lupenox', it informed the stock exchanges.
"Lupin has always made quality products affordable to Indian patients. Our tie-up with ItalFarmaco is yet another effort in this direction. We believe Lupenox, being a superior quality product sourced from ItalFarmaco's USFDA approved facility, will serve the needs of patients better," the company's president (India Region Formulations) Sakti Chakraborty said.
Lupin's shares were trading at Rs 1,220.15, up 3.40per cent, at the BSE.
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Investments Discussion Group
